Samsara BioCapital’s Avadel Pharmaceuticals AVDL Stock Holding History

Samsara BioCapital’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-675,504	Closed	-$10.3M	–	23
2025 Q3	$10.3M	Hold	675,504	–	–	1.35%	12
2025 Q2	$5.98M	Sell	675,504 -292,023	-30%	-$2.57M	1.22%	15
2025 Q1	$7.58M	Hold	967,527	–	–	1.35%	13
2024 Q4	$10.2M	Hold	967,527	–	–	1.4%	12
2024 Q3	$12.7M	Hold	967,527	–	–	2.44%	10
2024 Q2	$13.6M	Hold	967,527	–	–	2.85%	9
2024 Q1	$16.3M	Hold	967,527	–	–	2.53%	10
2023 Q4	$13.7M	Hold	967,527	–	–	2.13%	13
2023 Q3	$9.97M	Hold	967,527	–	–	3.05%	10
2023 Q2	$15.9M	Sell	967,527 -441,882	-31%	-$5.74M	2.8%	7
2023 Q1	$12.9M	Buy	1,409,409 +750,000	+114%	+$6.17M	2.67%	10
2022 Q4	$4.72M	Hold	659,409	–	–	1.02%	21
2022 Q3	$3.3M	Hold	659,409	–	–	0.77%	28
2022 Q2	$1.61M	Hold	659,409	–	–	0.43%	38
2022 Q1	$4.5M	Hold	659,409	–	–	1.13%	22
2021 Q4	$5.33M	Buy	659,409 +110,159	+20%	+$1.01M	1.03%	23
2021 Q3	$5.38M	Hold	549,250	–	–	0.84%	27
2021 Q2	$3.7M	Hold	549,250	–	–	0.46%	32
2021 Q1	$4.96M	Buy	549,250 +115,000	+26%	+$930K	0.92%	26
2020 Q4	$2.9K	Buy	+434,250	New	+$2.72M	0.29%	33

Other funds holding AVDL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital's AVDL Position: Q4 2025 in Review

Samsara BioCapital sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 675,504 shares — an estimated $10.3M sold.

Samsara BioCapital first reported a position in AVDL in Q4 2020 and held it in 20 quarters. The position peaked at $16.3M in Q1 2024. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

Samsara BioCapital reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Samsara BioCapital sold 675,504 Avadel Pharmaceuticals shares in Q4 2025, an estimated $10.3M.
Samsara BioCapital first reported a position in Avadel Pharmaceuticals in Q4 2020 and held it in 20 quarters.
Samsara BioCapital's Avadel Pharmaceuticals position peaked at $16.3M in Q1 2024.
207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Samsara BioCapital's 13F filing for Q4 2025, filed 17 Feb 2026.